1 BTC
=
- USD
MRBL Enhanced Equity ETF
As of May 30, 2026 at 09:55 UTC
Chart
About MRBL Enhanced Equity ETF
No description available.
Market Statistics
Trading Metrics
How to Buy EDGE
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy EDGE
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
3 articlesThe oncology landscape is experiencing rapid regulatory advancement as precision medicine and genomics expand significantly. Multiple biotech companies are advancing cancer therapies toward accelerated FDA approvals in 2026, with the precision medicine market projected to grow from $138.67 billion in 2026 to $537.17 billion by 2035. Key developments include Oncolytics' pelareorep showing strong response rates in anal cancer, CG Oncology's Phase 3 trial ahead of schedule, Zentalis advancing azenosertib in ovarian cancer, ArriVent initiating a pivotal Phase 3 study for firmonertinib, and PDS Biotechnology gaining FDA alignment on trial endpoints.
PDS Biotechnology announced a registered direct offering of 5.8 million shares and warrants, expecting to raise $5.3 million upfront with potential additional $5.8 million from warrant exercises. The proceeds will support the VERSATILE-003 Phase 3 clinical trial and other research and development expenses.
PDS Biotechnology reported a Q2 2025 net loss of $0.21 per share, beating analyst expectations. The company continues advancing its immunotherapy platforms in oncology and infectious disease, with notable progress in clinical trials for HPV and colorectal cancer treatments.
